Your browser doesn't support javascript.
loading
Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis.
Grenet, G; Le, H H; Bejan-Angoulvant, T; Erpeldinger, S; Boussageon, R; Kassaï, B; Moulin, P; Gueyffier, F; Cucherat, M.
Afiliação
  • Grenet G; Service de pharmacotoxicologie, hospices civils de Lyon, CHU de Lyon, 69424 Lyon, France; CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France. Electronic address: guillaume.grenet@chu-lyon.fr.
  • Le HH; CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France.
  • Bejan-Angoulvant T; Service de pharmacologie clinique, CHRU de Tours, 37044 Tours, France; UMR 7292 GICC, CNRS, 37044 Tours, France; Université François-Rabelais, 37044 Tours, France.
  • Erpeldinger S; University College of General Medicine, University Claude-Bernard Lyon 1, 69000 Lyon, France.
  • Boussageon R; Département de médecine générale, université de Poitiers, 86073 Poitiers, France.
  • Kassaï B; Service de pharmacotoxicologie, hospices civils de Lyon, CHU de Lyon, 69424 Lyon, France; CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France.
  • Moulin P; Fédération d'endocrinologie, maladies métaboliques, diabète et nutrition, hospices civils de Lyon, hôpital Louis-Pradel, 69500 Bron, France; Inserm U1060, université Lyon 1, 69622 Villeurbanne, France.
  • Gueyffier F; Service de pharmacotoxicologie, hospices civils de Lyon, CHU de Lyon, 69424 Lyon, France; CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France.
  • Cucherat M; Service de pharmacotoxicologie, hospices civils de Lyon, CHU de Lyon, 69424 Lyon, France; CNRS, laboratoire de biométrie et biologie évolutive UMR5558, université Lyon, université Lyon 1, 69622 Villeurbanne, France.
Diabetes Metab ; 45(6): 550-556, 2019 12.
Article em En | MEDLINE | ID: mdl-31150802
ABSTRACT

AIM:

Recent US recommendations indicate a target blood pressure (BP) of 130/80mmHg for patients with type 2 diabetes (T2D). Our aim was to characterize the association between risk of cardiovascular events and differences in BP decreases in randomized trials of a T2D population.

METHODS:

A systematic search was made for randomized clinical trials assessing the effects of antihypertensive treatments in T2D patients on mortality, and fatal and non-fatal cardiovascular events, using a meta-regression technique to explore the influence of BP decreases on treatment effects.

RESULTS:

A total of 88,503 patients from 44 randomized trials were included. There was no significant association between BP decreases and risk of all-cause or cardiovascular mortality, cardiovascular events or myocardial infarction. However, stroke risk was influenced by BP decreases compared with no reduction, a 10-mmHg reduction in systolic BP was associated with a relative odds ratio (OR) decrease of 33% (OR 0.67, 95% CI 0.54-0.82), and a 5-mmHg diastolic BP reduction was associated with a relative OR decrease of 38% (OR 0.62, 95% CI 0.50-0.76). Restricting the analysis to double-blind studies did not change the results for diastolic BP.

CONCLUSION:

A reduction in BP lowers the risk of stroke, but does not appear to affect the risk of other cardiovascular events in a T2D population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Anti-Hipertensivos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Anti-Hipertensivos Idioma: En Ano de publicação: 2019 Tipo de documento: Article